Industry & Intelligence
A Market That Cannot Be Wished Away
Britain has one of the largest illegal cannabis markets in Europe. Estimates consistently place annual consumption in the millions of users, with the illicit trade generating billions in untaxed revenue — revenue that funds criminal networks, bypasses any form of quality control, and reaches young people with no meaningful barrier to access.
Yet British law continues to treat cannabis primarily as a criminal matter. Possession can result in prosecution. Supply is an offence regardless of context. And despite decades of enforcement, the market has not shrunk. It has simply remained invisible to regulators.
A growing chorus of voices in the UK — including senior figures from the public health, economic, and political spheres — is now arguing that this approach has run its course. The debate is no longer whether cannabis is used in Britain. It is whether that use should take place under state oversight or criminal management.
The Regulatory Case, Plainly Stated
The argument for regulated adult-use cannabis in the UK does not rest on the claim that cannabis is harmless. It does not. Heavy or early-onset use carries documented risks, including associations with psychosis in vulnerable individuals and developmental impacts in adolescents. These are not talking points to be dismissed.
Rather, the case for regulation rests on a straightforward observation: prohibition has not managed those risks. It has simply removed the state from any position to manage them at all.
Under a regulated framework, products can be tested for potency and contaminants. Packaging can carry health warnings. Retailers can enforce age restrictions. Tax receipts can fund the health services that treat cannabis-related harms. None of those mechanisms exist in an illegal market, where the only quality assurance is the word of a dealer.
Canada's post-2018 experience is frequently cited in this context. The country shifted a substantial majority of cannabis purchases — now estimated at roughly three-quarters of transactions — into the licensed retail sector within a few years of federal legalisation. The illicit market has not been eliminated, but it has been progressively displaced by a system with accountability, traceability, and public health infrastructure built in.
Where Europe Stands
The UK's domestic debate does not occur in a vacuum. Across the Channel, European approaches to cannabis are in measurable flux. Germany's phased reform — now permitting personal possession and home cultivation for adults — has reshaped the political conversation across the continent. Luxembourg has moved towards regulated home cultivation. The Netherlands continues its longstanding tolerance policy while debating how to regularise supply. France, long a prohibition holdout, is revisiting enforcement priorities under sustained public and parliamentary pressure.
Malta occupies a specific and instructive position in this landscape. The country was the first EU member state to legalise personal adult-use cannabis and establish a nonprofit associative model for cultivation and distribution. That model — overseen by the Authority on the Responsible Use of Cannabis (ARUC) — places harm reduction and community accountability at the centre of the regulatory architecture, rather than commercial extraction of revenue.
The contrast with a hypothetical UK commercial market is worth noting. Where a large-economy model might prioritise tax yield and industry scale, Malta's framework was designed explicitly to minimise commercial incentives, restrict advertising, and embed health guidance throughout the distribution chain. ARUC has maintained that the island's approach is not a template for mass-market legalisation, but a deliberate experiment in keeping the market small, visible, and proximate to public health goals.
What Britain Could Learn From Smaller Models
The UK's scale makes a Malta-style associative model unlikely — the logistics alone would strain any regulatory body attempting to manage consumer demand across a population of 68 million. But the philosophical underpinning of Malta's approach carries transferable lessons: that regulation should be designed to protect health, not to maximise commercial opportunity; that advertising restrictions matter; and that enforcement against the illicit market must be sustained, not treated as a solved problem the moment the first licensed shop opens.
These are not novel observations. They feature in virtually every serious regulatory design document produced in Europe over the past decade. The challenge for any UK government is whether the political will exists to implement them with the discipline they require — or whether legalisation, if it comes, becomes a revenue exercise with health safeguards bolted on as an afterthought.
The Broader Stakes
Europe is watching the UK's cannabis debate with interest, not least because Britain's size means any regulatory shift would carry substantial market and political weight. A UK framework that prioritises robust harm reduction could lend credibility and momentum to reform efforts elsewhere. A poorly designed one — captured by commercial interests, weak on enforcement, or light on public health infrastructure — could set the cause back by providing ammunition to those who argue that legalisation inevitably means liberalisation without limits.
The core question, as several European policymakers have framed it, is whether governments choose to regulate cannabis or allow the illicit market to regulate it by default. Britain has deferred that question for decades. The pressure to answer it is becoming harder to ignore.
By Anna Micallef
Sources:
Omar Khan, "Opinion: New Labour Administration Can End Britain's Failed Cannabis Experiment," Business of Cannabis. https://businessofcannabis.com/opinion-new-labour-administration-can-end-britains-failed-cannabis-experiment/
Featured image: Photo by Adrian Dorobantu on Pexels
Members Discussion